Table 2.
Treatment results at 18-month follow-up.
| Parameter | Total | P value | |
|---|---|---|---|
| Baseline | 18 months | ||
| No. of eyes | 25 | 25 | |
| BCVA (LogMAR) | 3.46 ± 0.81 | 2.66 ± 1.05 | <0.001 |
| 3 (12%, stable) | |||
| 22 (88%, improved) | |||
|
| |||
| IOP (mmHg) | 42.2 ± 8.5 | 15.56 ± 2.0 | <0.001 |
| Topical antiglaucoma medication | 2.72 ± 0.45 | 0.87 ± 0.40 | <0.001 |
| NVI grade | |||
| Grade 0 | 0 (0) | 23 (92) | <0.001 |
| Grade 1 | 0 (0) | 2 (8) | |
| Grade 2 | 5 (20) | 0 (0) | |
| Grade 3 | 9 (36) | 0 (0) | |
| Grade 4 | 11 (44) | 0 (0) | |
|
| |||
| Anterior chamber angle | |||
| 180° closed | 6 (24) | 6 (24) | |
| 270° closed | 8 (32) | 8 (32) | |
| 360° closed | 11 (44) | 11 (44) | |
Values are presented as number (%) or mean ± SD. BCVA: best-corrected visual acuity; IOP: intraocular pressure; NVI: neovascularization of the iris. ∗P < 0.05 is considered statistically significant.